By David SachsValiRx shares fell Friday after it ended an agreement with Hokkaido University to research a potential oncology drug. Shares at 0721 GMT were down 1.25 pence, or 14%, at 8.0 pence. The U.K. drug development company, which specializes in cancer and women's health, said the partnership ended after the product was deemed unsuitable for further development. ValiRx has given the research data to the Japanese university, it said.

Source: Wall Street Journal June 16, 2023 07:23 UTC